Coeptis Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company focusing on advancing cell therapy platforms for various diseases, recently announced that it has successfully regained compliance with Listing Rule 5550(a)(2) of the Nasdaq Hearings Panel. The company had previously received a written notice from The Nasdaq Stock Market, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2) due to […]
Coeptis Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company focusing on advancing cell therapy platforms for various diseases, recently announced that it has successfully regained compliance with Listing Rule 5550(a)(2) of the Nasdaq Hearings Panel. The company had previously received a written notice from The Nasdaq Stock Market, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2) due to […]
